Birmingham Capital Management Co. Inc. AL Sells 30,994 Shares of Pfizer Inc. $PFE

Key Points

• Birmingham Capital Management Co. Inc. AL has reduced its stake in Pfizer by 19.0%, selling 30,994 shares and now holds 132,249 shares, valued at approximately $3,206,000.
• Pfizer reported $0.78 earnings per share (EPS) for the last quarter, surpassing analyst expectations of $0.58, with revenue also exceeding expectations at $14.65 billion.
• The biopharmaceutical company announced a quarterly dividend of $0.43 per share, resulting in a 7.0% dividend yield as part of its shareholder return strategy.

Birmingham Capital Management Co. Inc. AL decreased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 19.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 132,249 shares of the biopharmaceutical company's stock after selling 30,994 shares during the period. Pfizer accounts for approximately 1.4% of Birmingham Capital Management Co. Inc. AL's holdings, making the stock its 25th largest position. Birmingham Capital Management Co. Inc. AL's holdings in Pfizer were worth $3,206,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bessemer Group Inc. raised its position in Pfizer by 11.1% during the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after acquiring an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK increased its stake in shares of Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock worth $35,817,000 after purchasing an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp bought a new stake in shares of Pfizer in the 1st quarter valued at about $8,283,000. Westbourne Investments Inc. acquired a new stake in Pfizer in the 1st quarter valued at about $2,411,000. Finally, Bourne Lent Asset Management Inc. grew its holdings in Pfizer by 90.8% during the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company's stock worth $927,000 after purchasing an additional 18,200 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 1.2%

PFE stock opened at $24.52 on Monday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $29.36. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock has a market capitalization of $139.38 billion, a price-to-earnings ratio of 13.04, a PEG ratio of 0.81 and a beta of 0.55. The business's fifty day moving average price is $24.89 and its two-hundred day moving average price is $24.11.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the previous year, the business posted $0.60 earnings per share. Pfizer's quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent analyst reports. Wall Street Zen cut Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Weiss Ratings restated a "hold (c-)" rating on shares of Pfizer in a research note on Wednesday, October 8th. UBS Group reaffirmed a "neutral" rating and set a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Finally, Bank of America lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $28.13.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.